Nothing Special   »   [go: up one dir, main page]

CL2018000042A1 - Anticuerpos de unión a tau - Google Patents

Anticuerpos de unión a tau

Info

Publication number
CL2018000042A1
CL2018000042A1 CL2018000042A CL2018000042A CL2018000042A1 CL 2018000042 A1 CL2018000042 A1 CL 2018000042A1 CL 2018000042 A CL2018000042 A CL 2018000042A CL 2018000042 A CL2018000042 A CL 2018000042A CL 2018000042 A1 CL2018000042 A1 CL 2018000042A1
Authority
CL
Chile
Prior art keywords
binding antibodies
tau binding
tau
antibodies
union
Prior art date
Application number
CL2018000042A
Other languages
English (en)
Inventor
Kerry Louise Tyson
Terence Seward Baker
Georges Mairet-Coello
Patrick Downey
Jean-Philippe Courade
David Edward Ormonde Knight
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2018000042A1 publication Critical patent/CL2018000042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS DE UNIÓN A TAU Y FRAGMENTOS DE UNIÓN DE LOS MISMOS.</p>
CL2018000042A 2015-07-06 2018-01-05 Anticuerpos de unión a tau CL2018000042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175519 2015-07-06

Publications (1)

Publication Number Publication Date
CL2018000042A1 true CL2018000042A1 (es) 2018-06-01

Family

ID=53524638

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000042A CL2018000042A1 (es) 2015-07-06 2018-01-05 Anticuerpos de unión a tau

Country Status (23)

Country Link
US (4) US10344081B2 (es)
EP (1) EP3319984A1 (es)
JP (1) JP6937289B2 (es)
KR (1) KR20180027566A (es)
CN (1) CN107849105B (es)
AR (1) AR105266A1 (es)
AU (1) AU2016289753C1 (es)
BR (1) BR112017028101A2 (es)
CA (1) CA2991264C (es)
CL (1) CL2018000042A1 (es)
CO (1) CO2017012974A2 (es)
EA (1) EA036821B1 (es)
EC (1) ECSP18000844A (es)
IL (1) IL256687B (es)
MA (2) MA41669A1 (es)
MX (1) MX2017015908A (es)
PE (1) PE20180499A1 (es)
PH (1) PH12017502180A1 (es)
TN (1) TN2017000543A1 (es)
TW (1) TWI748954B (es)
UY (1) UY36774A (es)
WO (1) WO2017005732A1 (es)
ZA (1) ZA201708128B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
KR20180025962A (ko) 2015-07-06 2018-03-09 유씨비 바이오파마 에스피알엘 타우 결합 항체
KR20180027566A (ko) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
EP3579866A4 (en) * 2017-02-08 2020-12-09 Dragonfly Therapeutics, Inc. HEAVY CHAIN VARIABLE ANTIBODY DOMAINS WITH NKG2D RECEPTOR AIMING
MX2019009468A (es) 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
KR102225178B1 (ko) 2017-10-16 2021-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US20220017611A1 (en) * 2018-12-13 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
KR20220166308A (ko) * 2020-04-08 2022-12-16 얀센 바이오테크 인코포레이티드 항-phf-타우 항체 및 이의 용도
AU2021297873A1 (en) 2020-06-25 2023-02-09 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
ES2270421T3 (es) 1993-12-21 2007-04-01 Innogenetics N.V. Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones.
CA2195672A1 (en) 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
EP2259795B1 (en) * 2008-03-26 2016-04-06 Epitomics, Inc. Anti-vegf antibody
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA2765099A1 (en) 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2758433B1 (en) 2011-09-19 2017-10-18 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
KR20200013072A (ko) 2012-07-03 2020-02-05 워싱턴 유니버시티 Tau에 대한 항체
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
ES2775192T3 (es) * 2012-08-16 2020-07-24 Ipierian Inc Procedimientos de tratamiento de una tauopatía
EA035932B1 (ru) 2012-12-21 2020-09-02 Байоджен Ма Инк. Человеческие анти-тау антитела
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
WO2015091656A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
KR20180025962A (ko) 2015-07-06 2018-03-09 유씨비 바이오파마 에스피알엘 타우 결합 항체
KR20180027566A (ko) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها

Also Published As

Publication number Publication date
IL256687B (en) 2022-02-01
BR112017028101A2 (pt) 2018-09-04
EA036821B1 (ru) 2020-12-23
ZA201708128B (en) 2019-05-29
TWI748954B (zh) 2021-12-11
US10344081B2 (en) 2019-07-09
AR105266A1 (es) 2017-09-20
EA201890169A1 (ru) 2018-10-31
CN107849105A (zh) 2018-03-27
MA41669A1 (fr) 2018-05-31
MA42380A (fr) 2018-05-16
US20210139574A1 (en) 2021-05-13
EP3319984A1 (en) 2018-05-16
TW201713688A (zh) 2017-04-16
ECSP18000844A (es) 2018-03-31
AU2016289753B2 (en) 2020-11-26
WO2017005732A1 (en) 2017-01-12
CA2991264C (en) 2023-10-10
KR20180027566A (ko) 2018-03-14
US20230331833A1 (en) 2023-10-19
PE20180499A1 (es) 2018-03-09
JP2018519833A (ja) 2018-07-26
AU2016289753C1 (en) 2021-08-05
UY36774A (es) 2017-01-31
US20180194832A1 (en) 2018-07-12
JP6937289B2 (ja) 2021-09-22
MX2017015908A (es) 2018-03-15
US10906966B2 (en) 2021-02-02
CA2991264A1 (en) 2017-01-12
US20190375829A1 (en) 2019-12-12
CO2017012974A2 (es) 2018-03-09
PH12017502180A1 (en) 2018-05-28
IL256687A (en) 2018-03-29
US11746145B2 (en) 2023-09-05
CN107849105B (zh) 2021-09-17
NZ737843A (en) 2024-05-31
AU2016289753A1 (en) 2017-12-14
TN2017000543A1 (en) 2019-04-12

Similar Documents

Publication Publication Date Title
CL2018000042A1 (es) Anticuerpos de unión a tau
CL2018000043A1 (es) Anticuerpos de unión a tau
DK3625259T3 (da) Anti-sirpalpha-antistoffer
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MA46057A (fr) Anticorps anti-ctla4
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CU20170074A7 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
DK3313845T3 (da) Konjugater af cysteinmanipulerede antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
JP2016525099A5 (ja) 免疫グロブリンＦｃ断片のＦｃＲｎに対する結合親和力が維持される免疫グロブリンＦｃ結合体
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MA43715A (fr) Anticorps anti-tnf et fragments fonctionnels correspondants
MA50654A (fr) Anticorps anti-pacap
MA49289A (fr) Anticorps se liant à steap-1
DK3356398T5 (da) Fremgangsmåde til udvikling af monoklonale antistoffer
TH1601003730A (th) แอนติ-vista แอนติบอดี และชิ้นส่วนย่อย
TH1601002706A (th) แอนทิบอดีที่จำเพาะต่อ FcRn